Abstract
β-adrenergic agonists, and especially β2-adrenergic agonists, are generally prescribed for all asthmatics as backup medication to anti-inflammatory therapy or, in the case of exercise-induced asthma, as the primary drug. Technological advances have led to the development of increased β2-specific adrenergic agonists of longer duration of action. The effectiveness of β-adrenergic agonists in treating asthma is indisputable. However, the very effectiveness of these drugs causes problems of overuse, and consequent side effects, raising issues such as whether other drugs or other parameters should be preferentially utilized.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Reading
Blauw GJ, Westendorp RGJ. Asthma deaths in New Zealand: Whodunnit? Commentary. Lancet 1995; 345: 2–3.
Drotar DE, Davis EE, Cockcroft DW. Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice-daily treatment. Ann Allergy Asthma Immunol 1997; 79: 31–34.
Drugs for asthma Medical Letter 1995;37:1–4.
Furukawa CT, Kemp JP, Simons FER, Tinkelman DG. The proper role of 132-adrenergic agonists in the treatment of children with asthma. Pediatrics 1992; 90: 639–640.
Gibson P, Henry D, Francis L, Chuickshank D, Dupen F, Higginbotham N, et al. Association between availability of non-prescription beta 2 antagonist inhalers and undertreatment of asthma. BMJ 1993; 306: 1514–1518.
McFadden ER. Perspectives in (32-agonist therapy: Vox clamantis in deserto vel lux tenebris? J Allergy Clin Immunol 1995; 95: 641–651.
Mullen M, Mullen B, Carey M. The association between 13-agonist use and death from asthma. JAMA 1993; 270: 1842–1845.
Simons FER, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticosteroid treatment. Pediatrics 1997; 99: 655–659.
Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled p-agonists. Am J Respir Crit Care Med 1994; 149: 604–610.
Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, et al. Regular inhaled 13 agonist in asthma: Effects on exacerbations and lung function. Thorax 1993; 48: 134–138.
Taylor DR Sears MR. Regular beta-adrenergic agonists. Evidence, not reassurance, is what is needed. Chest 1994;106:552–559.
Wahedna I, Wong CS, Wisniewski AFZ, Pavord AD, Tattersfield AE. Asthma control during and after cessation of regular beta-2 agonist treatment. Am Rev Respir Dis 1993; 148: 707–712.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Furukawa, C.T. (2000). β-Adrenergic Agonists. In: Lieberman, P., Anderson, J.A. (eds) Allergic Diseases. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-007-0_18
Download citation
DOI: https://doi.org/10.1007/978-1-59259-007-0_18
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-4477-4
Online ISBN: 978-1-59259-007-0
eBook Packages: Springer Book Archive